- Home
- GLMD
as 04-02-2025 4:00pm EST
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
Upcoming Earnings Alert:
Get ready for potential market movements as Galmed Pharmaceuticals Ltd. GLMD prepares to release earnings report on 07 Apr 2025.
| Founded: | 2000 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 4.5M | IPO Year: | 2014 |
| Target Price: | N/A | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.33 - $23.80 | Next Earning Date: | 04-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Galmed Pharmaceuticals Ltd. News
GLMD Breaking Stock News: Dive into GLMD Ticker-Specific Updates for Smart Investing
PR Newswire
14 days ago
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy
Associated Press Finance
5 months ago
Galmed Pharmaceuticals: Q3 Earnings Snapshot
PR Newswire
6 months ago
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
PR Newswire
6 months ago
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
MT Newswires
7 months ago
Top Premarket Decliners
MT Newswires
7 months ago
Top Premarket Gainers
PR Newswire
a year ago
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
PR Newswire
a year ago
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
Compare GLMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLMD Galmed Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.